Full-Time

Associate Director

Medical Information

Updated on 8/24/2026

EVERSANA

EVERSANA

1,001-5,000 employees

Commercial services for pharmaceutical lifecycle management

No salary listed

London, UK

Remote

Must be legally eligible to work in the European Union or in the United Kingdom. Remote/home-office based; some travel may be required (up to ~10-15%).

Master's, MBA, PharmD

Category
Medical, Clinical & Veterinary (1)

Get referred to EVERSANA

See people who can refer or advise you

Requirements
  • Master of Science degree in Life Sciences or healthcare or equivalent.
  • 5+ years of Medical Information and/or pharmaceutical industry experience.
  • Knowledge of Medical Information Industry Best Practices.
  • Excellent interpersonal and communications skills, and the ability to listen to and understand complex issues and needs of various stakeholders including Corporate and Divisional personnel, staff members, clients/customers, vendors, technical/systems issues/limitations. Some of these issues/needs may conflict with other issues/needs, necessitating good judgment and the need for decisions that put the safety of patients and the delivery of our service to clients first.
  • Ability to effectively motivate/monitor/manage individuals to ensure performance of all required activities/tasks/functions.
  • Familiarity and understanding of EMA and local Regulations and European health-care systems affecting (biologics, pharmaceuticals, medical device manufacturers). In particular, detailed knowledge and understanding of the regulatory and compliance environment as it relates to the medical communications contact centre. Ability to keep up to date with all relevant changes to regulations or conditions affecting the operation of the European MI Department.
  • Familiarity and experience with planning/designing/delivering effective training programs, including an understanding of various learning styles and appropriate tailoring/customization of programs based on learning style.
Responsibilities
  • Manage direct reports, including mentoring, coaching, training, goal setting and feedback.
  • Direct the activities and responsibilities of the Medical Information Specialists, Medical Information Managers, and Medical Information Client Manager-Team Leads (CM-TL) who report to this position.
  • Support staff development and career development.
  • Support the hiring and recruitment of MICC staff.
  • Ensure client success by providing oversight of assigned clients, including implementation, ongoing management, regular touchpoints and meetings.
  • Understand client needs and ensure deliverables meet expectations, including KPI and service level agreements.
  • Assist with developing and executing Medical Information operational strategy and strategic initiatives.
  • Oversee Statement of Works (SOWs), invoicing, and client related Profit & Loss (P&L).
  • Understand client needs, pipeline, any significant organizational changes, and any product changes/new product approvals.
  • Direct the daily operations of the MICC. This includes active monitoring of current workload (call volume, inquiry volume, phone staffing/coverage) and making adjustments or directing/reassigning staff to specific tasks/functions as warranted.
  • Oversight and review of daily/monthly schedules, schedule planning, reviewing and approving or denying requests for PTO based on operational needs/workload/staffing.
  • Determine, plan and execute clinical, customer/client-service, or other training programs for the MICC staff.
  • Identify and deliver appropriate project management training programs to existing and emerging CM-TL.
  • Act as liaison with client stakeholders to manage all aspects related to services provided by EVERSANA Medical Information Contact Center Medical Communications (EVERSANA- MICC).
  • Participate in client audits and collaborate with EVERSANA Quality to facilitate audits.
  • Manage client invoicing.
  • Mentor junior staff. Provide initial and ongoing training to staff.
  • Ensure staff performance and proficiency across client product(s) & procedures.
  • Monitor and update client resources to ensure staff have the most accurate and current information.
  • Maintain client and client product information reference files.
  • Proactively monitor work processes related to handling medical information inquiries and ensure compliance with client performance requirements of EVERSANA-MICC.
  • Provide constructive suggestions and follow through with the implementation of appropriate changes. This may include revising/updating content or processes to meet EVERSANA- MICC service standards as well as the expectations and requirements of the client(s).
  • Provide medical information contact center support as needed.
  • Triage and respond to unsolicited medical information inquiries from health care professionals, consumers, and other contact center customers. Utilize medical information skills to identify, research, and critically evaluate medical literature to create responses to medical information inquiries.
  • Handle medical information requests across multiple channels and platforms (phone, email, CRM, live chat, etc.)
  • Identify and perform intake of adverse events and product complaints during interactions with customers in compliance with EVERSANA-MICC and client standard operating procedures. Knowledge of FDA’s post-marketing adverse event reporting regulations and safety terminology. Ability to make accurate assessments regarding what information needs to be obtained and the level or depth of information to be collected.
  • Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions of this position.
  • Interview, select and supervise staff; communicate company policies and procedures; determine job objectives, work methods and performance standards; review performance; authorize salary changes, promotions, transfers, discipline and discharge; administer personnel actions.
Desired Qualifications
  • Advanced Healthcare Degree (preferred PharmD or equivalent), Masters in Business Administration or Regulatory Science.
  • Pharmacist license.
  • More than five years of experience in Medical Information management role and/or relevant pharmaceutical industry management position.
  • Demonstrable skills in strategic/analytical thinking, people management/development, project management, and time management.
  • Technology proficiency in telephony, Medical Information database, Microsoft Office, and video conference platforms.
  • Fluent in English plus one or more other European language to the Common European Framework level B2, C1 or C2.
  • Innovator – Transforms creative ideas into original solutions that positively impact the company’s performance.
  • Highly Principled – Proves to be a professional of unquestionable integrity, credibility and character who demonstrates high moral and ethical behavior.

EVERSANA provides integrated commercial services to pharmaceutical and biotech companies across the product lifecycle. It helps with drug pricing, market access, reimbursement, patient adherence, and product delivery through a service-based model. Its solutions are delivered via a global network of 30+ locations, including consulting, market access strategies, patient services, and field deployment. The goal is to help clients bring products to market, optimize pricing and access, improve adherence, and ensure efficient delivery to improve patient outcomes and commercial performance.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Milwaukee, Wisconsin

Founded

2018

Get referred to EVERSANA

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • EVERSANA signed Candel Therapeutics and Xcovery launch deals in 2026, expanding pipeline.
  • Mike Guarino and Jen Norton appointments strengthen agency and market-access leadership in 2026.
  • August 20, 2026 platform expansion supports cross-sell into medical, commercial, and access teams.

What critics are saying

  • Integration risk remains high after the August 2025 Waltz merger and APACME carve-out.
  • Large clients can insource AI commercialization, shrinking EVERSANA's agency and services revenue in 2027.
  • If Candel's CAN-2409 launch or similar launches fail, EVERSANA loses marquee growth proof.

What makes EVERSANA unique

  • August 2026 AI Agency spans medical affairs, market research, field sales, and MLR automation.
  • EVERSANA combines commercialization, distribution, patient services, and payer connectivity inside one operating model.
  • The 2025 Waltz Health merger adds drug-pricing marketplaces and direct-to-payer capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Conference Attendance Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Aug 20th, 2026
EVERSANA expands AI-powered platform across medical affairs and commercial operations

EVERSANA has expanded its AI-powered commercialisation platform beyond marketing to include medical affairs, market research, and field sales team engagement. The platform, which combines agentic AI orchestration, workflow automation, and enterprise data capabilities, now offers solutions for medical information, market research, MLR automation, and analytics. The company is developing additional features for market access, patient services, and sales enablement. The platform aims to help life sciences organisations improve efficiency whilst maintaining industry compliance and governance requirements. "Organizations are moving beyond isolated AI pilots and looking for practical ways to scale AI across commercialisation," said Mark Thierer, EVERSANA's chief executive officer. The company serves more than 650 organisations globally. EVERSANA will showcase the platform at an event on 27 August in New York.

PR Newswire
Jun 9th, 2026
EVERSANA appoints Jen Norton as President of Market Access & Value to lead integrated business unit

EVERSANA, a global provider of commercial services to the life sciences industry, has appointed Jen Norton as President, Market Access & Value. Norton will lead a new dedicated market access business unit integrating EVERSANA's services across global pricing, revenue management, value and evidence, and consulting. Norton brings over 20 years of market access leadership experience. She joins from Takeda, where she served as Senior Vice President and Head of U.S. Patient and Market Access, and previously held senior positions at Amgen and Biogen. The new unit reinforces EVERSANA's commitment to helping clients navigate the complex pricing and access landscape. CEO Mark Thierer said successfully navigating market access is amongst the most critical challenges clients face today. EVERSANA serves over 650 organisations in the life sciences industry.

PR Newswire
May 6th, 2026
EVERSANA appoints Mike Guarino as CEO of global health agency EVERSANA INTOUCH

EVERSANA has appointed Mike Guarino as chief executive officer of EVERSANA INTOUCH, its global health agency. Guarino will lead strategy and operations across the agency's capabilities, focusing on integrating commercialisation opportunities through data and AI to deliver marketing solutions for life sciences clients. Guarino brings extensive agency experience, most recently serving as chief commercial officer at IPG Health. He spent over two decades in senior roles at FCB Health and co-founded Area 23. Senior leaders including Ann Cave, Susan Perlbachs, John Kenny and Dan Gandor will report to Guarino. Founder Faruk Capan will shift focus to expanding the company's AI Agency platform, launched in collaboration with Google in August 2025. EVERSANA provides commercial services to the life sciences industry, serving over 650 organisations globally.

PharmaLIVE
Apr 29th, 2026
Candel Therapeutics announces commercial agreement with EVERSANA to support U.S. launch of prostate cancer therapy.

Candel Therapeutics announces commercial agreement with EVERSANA to support U.S. launch of prostate cancer therapy. Candel Therapeutics, a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to help patients with cancer, today announced that it entered into a product commercialization agreement with EVERSANA, a provider of global commercialization services to the life sciences industry, to support the potential U.S. commercial launch of aglatimagene besadenovec (aglatimagene or CAN-2409) for the treatment of intermediate- to high-risk, localized prostate cancer. Under the terms of the agreement, EVERSANA will provide Candel with a broad suite of integrated commercialization services including data and analytics, medical affairs, market access, and field operations. EVERSANA joins IDEA Pharma, a division of SAI MedPartners (IDEA), which has been providing path-to-market strategies and strategic positioning for aglatimagene. Candel has worked in close collaboration with both EVERSANA and IDEA on key pre-commercial workstreams as previously announced during Candel's virtual Research and Development Day in December 2025. This collaboration reflects Candel's deliberate approach to building a world class commercial organization with global reach, designed from the ground up and leveraging a team of highly experienced professionals poised to support the potential commercial launch of aglatimagene for the treatment of intermediate- to high-risk, localized prostate cancer, subject to regulatory approval. This operating model gives Candel access to leading commercial capabilities while maintaining financial flexibility, capital efficiency, and scientific focus that has driven Candel's progress to date. "From the beginning, we designed Candel's commercial strategy around a partner-led model that allows us to stay focused on advancing the science and navigating the regulatory pathway, while having access to world-class commercial capabilities on demand," said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. "With the addition of EVERSANA, that model is fully in place, and with the progress we've already made across our pre-commercialization workstreams, we have confidence in our readiness for the potential commercial launch of aglatimagene for the treatment of intermediate- to high-risk, localized prostate cancer. We look forward to working with EVERSANA and IDEA Pharma in providing a novel and potentially invaluable therapeutic for localized prostate cancer patients." "We are proud to support Candel as it advances what could be a new and potentially transformative treatment option for patients with localized prostate cancer," said Gregory Skalicky, President of EVERSANA. "Candel's unique approach to commercialization, building a dedicated and flexible platform with specialized partners, rather than a fixed pharmaceutical infrastructure, is exactly the type of model EVERSANA was designed to support. We have already integrated our resources alongside the Candel team, with key commercial workstreams actively underway, and we look forward to helping ensure that aglatimagene reaches patients efficiently and effectively upon potential approval."

PR Newswire
Apr 27th, 2026
Xcovery partners with EVERSANA to expand US launch of lung cancer drug Ensacove

Xcovery Holdings has partnered with EVERSANA to support the US commercial launch of Ensacove (ensartinib), a novel therapy for adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK inhibitor. Under the agreement, EVERSANA will provide comprehensive end-to-end commercialisation services, including market access and commercial and medical teams. Ensacove is a next-generation ALK inhibitor jointly developed by Xcovery and Betta Pharmaceuticals and is now available in the United States. The partnership aims to expand patient access across the US by leveraging EVERSANA's commercialisation capabilities and experience in the life sciences industry. EVERSANA serves over 650 organisations globally, including pharmaceutical startups and established companies.